Skip to main content English

Presentation of the Phase II trial final results of HER-Vaxx, a B cell peptide-based Her-2/neu vaccine (Tobias et al, 2017, Wiedermann et al, 2021), at AACR Annual Meeting 2024

The poster presentation was given by Dr. Joshua Tobias at the American Association of Cancer Research (AACR) Annual Meeting (April 5-10, 2024; San Diego, CA, USA). Dr. Sharon Yavrom (in the Photo), a representative from the cooperation partner company Imugene Ltd, which has coordinated the Phase Ib and Phase II trial of HER-Vaxx, was also at the poster session.

A manuscript on the significant HER-Vaxx Phase II final results showing the vaccine's safety profile, clinical efficacy in terms of overall survival, progression-free survival, and tumor reduction, which significantly correlated with vaccine-induced immune responses, has now been reviewed for publication in the prestigious AACR journal 'Clinical Cancer Research'.